- Home
- VIVS vs TOVX Comparison
VIVS vs TOVX Comparison
Compare VIVS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- TOVX
- Stock Information
- Founded
- VIVS 2007
- TOVX 2001
- Country
- VIVS United States
- TOVX United States
- Employees
- VIVS N/A
- TOVX N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- TOVX Health Care
- Exchange
- VIVS Nasdaq
- TOVX Nasdaq
- Market Cap
- VIVS 3.6M
- TOVX 3.8M
- IPO Year
- VIVS N/A
- TOVX 2006
- Fundamental
- Price
- VIVS $1.84
- TOVX $0.47
- Analyst Decision
- VIVS
- TOVX Hold
- Analyst Count
- VIVS 0
- TOVX 1
- Target Price
- VIVS N/A
- TOVX N/A
- AVG Volume (30 Days)
- VIVS 71.5K
- TOVX 1.8M
- Earning Date
- VIVS 06-13-2025
- TOVX 05-14-2025
- Dividend Yield
- VIVS N/A
- TOVX N/A
- EPS Growth
- VIVS N/A
- TOVX N/A
- EPS
- VIVS N/A
- TOVX N/A
- Revenue
- VIVS $144,000.00
- TOVX N/A
- Revenue This Year
- VIVS $59.08
- TOVX N/A
- Revenue Next Year
- VIVS $18.24
- TOVX N/A
- P/E Ratio
- VIVS N/A
- TOVX N/A
- Revenue Growth
- VIVS N/A
- TOVX N/A
- 52 Week Low
- VIVS $1.56
- TOVX $0.40
- 52 Week High
- VIVS $21.96
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- VIVS N/A
- TOVX 29.91
- Support Level
- VIVS N/A
- TOVX $0.43
- Resistance Level
- VIVS N/A
- TOVX $0.54
- Average True Range (ATR)
- VIVS 0.00
- TOVX 0.05
- MACD
- VIVS 0.00
- TOVX 0.03
- Stochastic Oscillator
- VIVS 0.00
- TOVX 41.18
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.